SXI Life Sciences
|
6 673,38
|
-194,45
|
-2,83%
|
Analysen zu SXI Life Sciences-Werten
| 21.02.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 20.02.24 | Roche Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 07.02.24 | Novartis Buy | Deutsche Bank AG | |
| 07.02.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 06.02.24 | Novartis Underweight | Barclays Capital | |
| 06.02.24 | Novartis Buy | UBS AG | |
| 05.02.24 | Roche Sell | Deutsche Bank AG | |
| 05.02.24 | Novartis Buy | Jefferies & Company Inc. | |
| 05.02.24 | Roche Neutral | UBS AG | |
| 02.02.24 | Roche Kaufen | DZ BANK | |
| 02.02.24 | Roche Equal Weight | Barclays Capital | |
| 02.02.24 | Roche Sell | Deutsche Bank AG | |
| 02.02.24 | Novartis Buy | Deutsche Bank AG | |
| 01.02.24 | Roche Neutral | UBS AG | |
| 01.02.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 01.02.24 | Roche Hold | Jefferies & Company Inc. | |
| 31.01.24 | Novartis Kaufen | DZ BANK | |
| 31.01.24 | Novartis Buy | UBS AG | |
| 31.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 30.01.24 | Roche Neutral | UBS AG | |
| 30.01.24 | Novartis Buy | UBS AG | |
| 30.01.24 | Roche Sell | Deutsche Bank AG | |
| 22.01.24 | Roche Hold | Deutsche Bank AG | |
| 19.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 16.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 16.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 15.01.24 | Roche Neutral | UBS AG | |
| 15.01.24 | Novartis Buy | UBS AG | |
| 15.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 11.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 09.01.24 | Roche Equal Weight | Barclays Capital | |
| 09.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | UBS AG | |
| 05.01.24 | Novartis Buy | Deutsche Bank AG | |
| 03.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 03.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 02.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 21.12.23 | Novartis Underweight | Barclays Capital |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.